PA
PCVX icon

Profund Advisors’s Vaxcyte PCVX Stock Holding History

Profund Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.88M Sell
32,277
-4,119
-11% -$224K 0.05% 210
2026
Q1 		$2.11M Sell
36,396
-14,051
-28% -$763K 0.08% 187
2025
Q4 		$2.33M Buy
50,447
+17,525
+53% +$784K 0.07% 185
2025
Q3 		$1.19M Sell
32,922
-2,166
-6% -$71.8K 0.04% 290
2025
Q2 		$1.14M Buy
35,088
+6,692
+24% +$219K 0.04% 272
2025
Q1 		$1.07M Sell
28,396
-1,458
-5% -$117K 0.05% 282
2024
Q4 		$2.44M Buy
29,854
+15,157
+103% +$1.51M 0.09% 156
2024
Q3 		$1.68M Sell
14,697
-4,290
-23% -$387K 0.06% 223
2024
Q2 		$1.43M Sell
18,987
-2,442
-11% -$166K 0.05% 236
2024
Q1 		$1.46M Sell
21,429
-5,851
-21% -$405K 0.06% 239
2023
Q4 		$1.71M Sell
27,280
-1,602
-6% -$83.2K 0.07% 202
2023
Q3 		$1.47M Sell
28,882
-2,122
-7% -$105K 0.08% 192
2023
Q2 		$1.55M Sell
31,004
-3,082
-9% -$146K 0.08% 194
2023
Q1 		$1.28M Buy
+34,086
New +$1.45M 0.08% 234

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Profund Advisors's PCVX Position: Q2 2026 in Review

Profund Advisors reduced its Vaxcyte (PCVX) stake by 11% in Q2 2026, selling an estimated $224K and leaving 32,277 shares worth $1.88M. The position accounts for 0.05% of the portfolio, ranked #210.

Profund Advisors first reported a position in PCVX in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.44M in Q4 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Profund Advisors held 32,277 shares of Vaxcyte worth $1.88M as of Q2 2026.
  • Profund Advisors sold 4,119 Vaxcyte shares in Q2 2026, an estimated $224K.
  • Vaxcyte made up 0.05% of Profund Advisors's portfolio in Q2 2026, its #210 holding.
  • Profund Advisors first reported a position in Vaxcyte in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Vaxcyte position peaked at $2.44M in Q4 2024.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.